MedPath

Efzofitimod

Generic Name
Efzofitimod
Drug Type
Biotech
Unique Ingredient Identifier
V5TNN0W368
Background

Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

Clinical Trials
Related News

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Phase 2
Recruiting
Conditions
Interstitial Lung Disease
Interventions
Drug: Placebo
First Posted Date
2023-06-07
Last Posted Date
2025-05-07
Lead Sponsor
aTyr Pharma, Inc.
Target Recruit Count
25
Registration Number
NCT05892614
Locations
🇺🇸

aTyr Investigative Site, Richmond, Virginia, United States

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Phase 3
Active, not recruiting
Conditions
Pulmonary Sarcoidosis
Interventions
Drug: Placebo
First Posted Date
2022-06-10
Last Posted Date
2025-05-20
Lead Sponsor
aTyr Pharma, Inc.
Target Recruit Count
268
Registration Number
NCT05415137
Locations
🇬🇧

aTyr Investigative Site, London, United Kingdom

🇯🇵

Kyorin Investigative Site, Tokyo, Japan

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Phase 2
Completed
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Drug: Placebo
First Posted Date
2020-06-02
Last Posted Date
2023-08-18
Lead Sponsor
aTyr Pharma, Inc.
Target Recruit Count
36
Registration Number
NCT04412668
Locations
🇺🇸

aTyr Investigative Site, Toledo, Ohio, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy